Partial
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are broadly consistent with the CERIANNA label (PET imaging; adjunct to biopsy for ER-positive recurrent/metastatic breast cancer; indication depends on labeling). However, one statement overreaches by asserting FDA approval includes formulation/preparation/administered as part of approved labeling, which is not supported by the provided label excerpts.
Category Scores
Accurate Statements
Cerianna is an FDA-approved imaging agent used in positron emission tomography (PET).
Section 1: "CERIANNA is indicated for use with positron emission tomography (PET) imaging..."
Cerianna is used to help doctors evaluate certain cancers.
Section 1: "...for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer."
Cerianna’s FDA-approved use depends on the indication(s) listed in its prescribing information.
Section 1 (Indications and Usage): provides the labeled indication and limitations of use relevant to what it is approved to detect.
Unsupported Statements
FDA approval includes the drug product formulation and how it is prepared/administered as part of the approved labeling.
Not supported by the supplied label excerpts; the excerpts do not address what aspects of approval include formulation/preparation/administration beyond providing dosing and radiation safety handling instructions.
Contradictions
Important Omissions
The indication-specific limitation that CERIANNA is an adjunct to biopsy for recurrent or metastatic breast cancer and is not useful for imaging other receptors (e.g., HER2, PR) is not explicitly stated in the AI claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The main statements are generally consistent with labeled use for PET imaging of ER-positive lesions in recurrent/metastatic breast cancer. The unsupported statement concerns regulatory framing rather than clinical use instructions; no dosing, contraindication, or warning claims were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One regulatory/approval-scope statement is not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or rephrase the approval-scope claim; align wording to the label’s specific indication and limitations (adjunct to biopsy; ER-positive lesions; not useful for HER2/PR imaging).